CClinicalTrials.gg
Sign In
TerminatedNCT05839626Updated May 27, 2026

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

A Phase 1 interventional study of SAR445514 in Relapsed/Refractory Multiple Myeloma and Amyloid Light-chain Amyloidosis, sponsored by Sanofi. Terminated at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Why this study was terminated
Early discontinuation based on sponsor decision not driven by any safety concerns; phase 2 was not initiated.
Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH) Phase 1/Phase 2 study for evaluating SAR445514 in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light chain amyloidosis (RRLCA).

The study will comprise 3 parts:

A dose escalation phase (Part 1) in RRMM participants (Part 1a) that will evaluate several doses administered to determine 2 doses that will be tested in the dose optimization part.

A dose escalation will also be done in RRLCA participants (Part 1b) but started sequentially after the end of the dose escalation in RRMM participants. This dose escalation will evaluate the 2 doses planned to be used in dose optimization in RRMM, to ensure those doses are safe also for RRLCA participants.

A dose optimization phase (Part 2) that will be evaluating 2 doses determined from Part 1 to determine the preliminary recommended Phase 2 dose (pRP2D) and schedule for SAR445514 in RRMM.

A dose expansion phase (Part 3) that will evaluate the preliminary efficacy of pRP2D and schedule for SAR445514 in RRMM (Part 3a) and RRLCA (Part 3b).

Approximately 111 participants will be enrolled and treated by study intervention and separated as such:

Part 1a: Approximately 30 to 40 participants Part 1b: Approximately 6 to 12 participants Part 2: Approximately 30 participants Part 3a: Approximately 15 participants Part 3b: Approximately 14 participants

Read the detailed description

The duration of the study for a participant will include A screening period: up to 28 days prior day 1 of cycle 1 (C1D1) A treatment period: enrolled participants will receive administration of 4 weeks cycles of SAR445514 subcutaneously.

The End of treatment visit will occur 30 days (+/- 7 days) from last investigational medicinal product (IMP) administration or prior initiation of further therapy, whichever comes first.

The follow-up period will continue until death, participant's request to discontinue study, final Overall Survival analysis or upon cancellation of survival follow-up at the discretion of the Sponsor at any timepoint.

02

Conditions studied

  • Relapsed/Refractory Multiple Myeloma
  • Amyloid Light-chain Amyloidosis
03

In context

Multiple Myeloma

3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.

This study's enrollment of 32 is below the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.

Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Participants must have a documented diagnosis of multiple myeloma (Part 1a, 2, and 3a) or light chain amyloidosis (Part 1b and 3b).

Participants with RRMM (Part 1, 2, and 3a)

  • Participants with measurable disease for RRMM
  • Participants with MM must have received at least 2 prior lines of therapy which must include at least 2 consecutive cycles of a second or third generation immunomodulator, steroid, proteasome inhibitor and anti-CD38 monoclonal antibody (MoAb).
  • Participants must have documented evidence of progressive disease (PD), as per IMWG 2016 criteria.

Participants with RR LCA (Part 1b and 3b) must have received at least 1 prior line of treatment comprising at least 1 proteasome inhibitor.

  • Participants with measurable disease according to ISA 2012.
  • Participants must have documented evidence of progressive disease (PD), as per ISA 2012 criteria.
  • One or more organ impacted by amyloidosis as per National comprehensive cancer network (NCCN) guidelines.

For dose escalation, body weight within 40 to 120 kg

Capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Medical conditions

  • Primary refractory MM defined as participants who never achieved at least a minimal response with any treatment during the disease course
  • Second primary malignancy

Participants with RRMM (Part 1a, 2, and 3a)

  • For MM participants, primary systemic LCA and plasma cell leukemia
  • For MM participants, congestive heart failure (New York Heart Association [NYHA]) Grade ≥II; cardiomyopathy, active ischemia, or any other uncontrolled cardiac condition

Participants with RR LCA (Part 1b and 3b)

  • For LCA participants, evidence of clinically significant cardiovascular condition, defined as one or more of the following:

    1. N-terminal prohormone of brain natriuretic peptide (NT-proBNP) >8500 ng/mL
    2. New York Heart Association (NYHA) classification III or IV heart failure
    3. Heart failure that, in the opinion of the Investigator, is not primarily related to LCA cardiomyopathy (including, but not limited to, ischemic heart disease, uncorrected valvular disease, infections)
    4. Prior event (history) in the last 6 months of acute coronary syndrome, myocardial infarction or unstable angina as well as participants who during the last 6 months experienced a percutaneous cardiac intervention with stent and/or a coronary artery bypass
    5. Hospitalization in the last 4 weeks prior to treatment related to a cardiovascular event
    6. Participants with prior history of arrhythmia and/or cardiac conduction disorders for which a pacemaker or an implantable cardioverter defibrillator (ICD) is required but has not been placed. This includes, but may not be limited to, sustained ventricular tachycardia, association of an atrioventricular, or sinoatrial nodal dysfunction
  • For LCA participants, a systolic blood pressure \<100 mmHg or a diastolic blood pressure \<55 mmHg.
  • For LCA participants: previous or current diagnosis of symptomatic MM, including the presence of lytic bone disease, plasmacytomas, ≥60% plasma cells in the BM, or hypercalcemia.

All participants

  • Uncontrolled infection within 14 days prior to study treatment.
  • Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A (defined as positive hepatitis A antigen or positive IgM); HIV serology at screening will be tested for participants in countries where it is required by local regulations.
  • Uncontrolled or active hepatitis B virus (HBV) infection: participants with positive B surface antigen (HBsAg) and/or HBV deoxyribonucleic acid (DNA)
  • Active hepatitis C virus (HCV) infection: positive HCV ribonucleic acid (RNA) and negative anti-HCV.

Prior/concomitant therapy

  • Any anti-MM drug treatment within 14 days before study treatment
  • Prior allogenic hematopoietic stem cell (HSC) transplant with active graft-versus-host disease (GvHD) (GvHD any grade and/or being under immunosuppressive treatment within the last 2 months prior to first IMP).
  • Any major procedure within 14 days before the initiation of the study treatment
  • Administration of an anti-CD38 monoclonal antibody (isatuximab or daratumumab) less than 90 days prior to the first administration of study treatment.
  • Administration of an anti-BCMA agent (including, but not limited to, CAR T-cells, TCEs, antibody drug conjugate) less than 21 days prior to the administration of study treatment.
  • Unresolved toxicities from prior anticancer therapy, defined as not having resolved to CTCAE Version 5.0 Grade 1, at the exception of residual Grade 2 peripheral neurotoxicity related to bortezomib and/or thalidomide and considered as stable.
  • Participants with a contraindication to dexamethasone.

Prior/concurrent clinical study experience

  • Received any other investigational drugs or prohibited therapy for this study within 28 days or 5 half-lives from study treatment, whichever is shorter

Diagnostic assessments

  • Hemoglobin \<8 g/dL (5.0 mmol/L)
  • Platelets \<50 × 10\^9/L (not permissible to transfuse a participant within 1 week prior to the screening platelet count to reach this level).
  • Absolute neutrophil count (ANC) \<1000 μL (1 × 10\^9/L).
  • Creatinine clearance \<30 mL/min (Modification of Diet in Renal Disease Formula).
  • Total bilirubin >1.5 × upper limit of normal (ULN) (unless the subject has documented Gilbert syndrome in which case direct bilirubin should not be >2.5 × ULN).
  • Aspartate aminotransferase (AST/SGOT) or Alanine aminotransferase (ALT/SGPT) >2.5 × ULN.
  • Participants with Grade 3 or 4 hypercalcemia (corrected serum calcium of >12.5 mg/dL; >3.1 mmol/L; ionized calcium >1.6 mmol/L; or requiring hospitalization) will not be eligible unless participants recover to Grade 2 or less under anti-hypercalcemia treatment.

Other exclusions

  • Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    SAR445514 RRMM Dose escalation phase (Part 1a)

    SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)

    Drug: SAR445514

  • Experimental
    SAR445514 RRLCA Dose escalation phase (part 1b)

    SAR445514 will be administered to participants with relapsed/refractory light chain amyloidosis (RRLCA)) using subcutaneous route (SC)

    Drug: SAR445514

  • Experimental
    SAR445514 Dose level A (part 2)

    SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)

    Drug: SAR445514

  • Experimental
    SAR445514 Dose level B (part 2)

    SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)

    Drug: SAR445514

  • Experimental
    SAR445514 RRMM Dose expansion (part 3a)

    SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)

    Drug: SAR445514

  • Experimental
    SAR445514 RRLCA Dose expansion (part 3b)

    SAR445514 will be administered to participants with relapsed/refractory light chain amyloidosis (RRLCA) using subcutaneous route (SC)

    Drug: SAR445514

Interventions

  • DrugSAR445514

    Powder for solution for injection. Sub Cutaneous administration.

06

What researchers measure

Primary outcomes

  1. Dose escalation (part 1a - RRMM) Presence of dose limiting toxicities (DLT)

    DLTs will be defined using NCI CTCAE version 5.0 or ASTCT criteria for CRS or ICANS.

    Time frame: Cycle 1 - 4 weeks per cycle

  2. Dose escalation (part 1a - RRMM) Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Presence of TEAEs, SAEs, and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading

    Time frame: From Baseline to end of follow-up (approx. 15 months)

  3. Dose optimization (part 2 - RRMM) Overall response rate (ORR)

    ORR is defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria, after the last participant is treated for at least 4 cycles or prematurely discontinued.

    Time frame: Cycles 1 to 4 - 4 weeks per cycle

  4. Dose escalation (part 1b - RRLCA) Presence of dose limiting toxicities (DLT) at cycle 1

    Time frame: Cycle 1 - 4 weeks per cycle

  5. Dose escalation (part 1b - RRLCA) Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Time frame: From baseline to end of follow-up (approx. 15 months)

  6. Dose expansion (part 3 - RRMM) Overall response rate (ORR)

    ORR is defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria.

    Time frame: Cycles 1 to 4 - 4 weeks per cycle

  7. Dose expansion (part 3-RRLCA) Hematological response (HR)

    HR is defined as the proportion of participants with sCR, CR, VGPR, and PR according to the European society of hematology/International society of hematology working group guidelines.

    Time frame: Cycles 1 to 4 - 4 weeks per cycle

Secondary outcomes

  1. Dose escalation (part 1 - RRMM) Overall response rate (ORR)

    ORR defined as the proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria.

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  2. Dose optimization (part 2 - RRMM) Presence of dose limiting toxicities (DLT)

    Time frame: Cycles 1 to 4 - 4 weeks per cycle

  3. Dose optimization (part 2 - RRMM) Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Treatment-emergent adverse events (AEs) are defined as AEs that develop, worsen, or become serious during the treatment period. The treatment period is defined as the time from first dose of study treatment up to 30 days after last dose of study treatment.

    Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (approx. 1 year with cycle of 28 days)

  4. Dose optimization & expansion (Part 2 & Part 3a - RRMM) Very Good Partial Response (VGPR) or Better Rate

    VGPR is defined as the proportion of participants with sCR, CR, and VGPR according to the 2016 IMWG criteria.

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  5. Dose optimization & expansion (Part 2 & Part 3a - RRMM) Duration of response (DOR)

    DOR is defined as the time from the date of the first response to the date of the first occurrence of progressive disease (PD as determined by the investigator or death from any cause, whichever happens first. DOR is determined only for participants who have achieved a response (PR or better).

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  6. Dose optimization & expansion (Part 2 & Part 3a - RRMM) Time to first response (TT1R)

    TT1R is defined as the time from the date of the first response to the date of the first occurrence of progressive disease (PD as determined by the investigator or death from any cause, whichever happens first. DOR is determined only for participants who have achieved a response (PR or better).

    Time frame: Cycle 1 to first progressive disease or end of treatment whichever comes first (approx. 1 year with cycle of 28 days)

  7. Dose optimization & expansion (Part 2 & Part 3a -RRMM) Time to best response (TTBR)

    TTBR is defined as the time from the first administration of the IMP to the date of first occurrence of best overall response (PR or better that is subsequently confirmed.

    Time frame: Cycle 1 to first progressive disease or end of treatment whichever comes first (approx. 1 year with cycle of 28 days)

  8. Dose optimization & expansion (Part 2 & Part 3a - RRMM) Progression free survival (PFS)

    PFS is defined as the time from the date of the first administration of the IMP to the date of first documentation of progressive disease or the date of death from any cause, whichever comes first. Responses will be determined according to IMWG criteria. Progression based on paraprotein will be confirmed based on two consecutive assessments.

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  9. Dose optimization & expansion (Part 2 & Part 3a - RRMM) Overall survival (OS)

    OS is defined as the time from the date of the first administration of the IMP to death from any cause

    Time frame: Cycle 1 to end of follow-up or death (approx. 15 months with cycle of 28 days)

  10. Dose optimization & expansion (Part 2 & Part 3a - RRMM) Clinical benefit rate (CBR)

    CBR is the rate of participants with confirmed CR or PR at any time or stable disease (SD) of at least 6 months from the first IMP administration determined by the Investigator per IMWG 2016 criteria.

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  11. Dose escalation (part 1b - RRLCA) Overall Hematological Response (OHR)

    OHR is defined as the proportion of participants with CR, VGPR, and PR according to the International Society of Amyloidosis guidelines (ISA 2012).

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  12. Dose extension (part 3b - RRLCA) Hematological complete response rate (HCR).

    HCR is defined as the proportion of participants with complete response according to the ISA 2012.

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  13. Dose extension (part 3b - RRLCA) Hematological very good partial response rate or better (HVGPR)

    HVGPR defined as proportion of participants with very good partial response and CR as per ISA 2012 criteria

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  14. Dose expansion (part 3b - RRLCA) Overall survival (OS)

    OS is defined as the time from the date of study entry to death from any cause.

    Time frame: Cycle 1 to death or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  15. Dose expansion (part 3b - RRLCA) Progression-Free Survival (PFS)

    PFS is defined as time from the time from the first administration of the IMP to any of the following: hematological progression, major organ progression (cardiac, kidney or liver) according to ISA 2012 criteria or death by any cause.

    Time frame: Cycle 1 to first progressive disease (organ or hematological) or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  16. Dose expansion (part 3b - RRLCA) Time to first hematological response (TT1HR)

    TT1HR is defined as the time from the first administration of the IMP to the date of first hematological response (PR or better) that is subsequently confirmed.

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  17. Dose expansion (part 3b - RRLCA) Duration of hematological response (DOHR)

    DOHR is defined as time from the time from the first administration of the IMP to any of the following: hematological progression, major organ progression (cardiac, kidney or liver) according to ISA 2012 criteria or death by any cause.

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

  18. Dose expansion (Part 3 - RRMM & RRLCA) Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Treatment-emergent adverse events (AEs) are defined as AEs that develop, worsen, or become serious during the treatment-emergent period.

    Time frame: From first dose of study treatment up to 30 days after last dose of study treatment (approx. 15 months with cycle of 28 days)

  19. Incidence rate of infusion associated reactions (IARs)

    Time frame: From cycle 1 to end of treatment (approx. 1 year with cycle of 28 days)

  20. Incidence rate of injection site reactions (ISR)

    Time frame: From cycle 1 to end of treatment (approx. 1 year with cycle of 28 days)

  21. Incidence of laboratory abnormalities

    Time frame: From cycle 1 to end of follow-up (approx. 15 months with cycle of 28 days)

  22. Assessment of pharmacokinetics (PK) parameter of SAR445514: Ctrough

    Time frame: From cycle 1 to end of treatment (approx. 1 year with cycle of 28 days)

  23. Assessment of pharmacokinetics (PK) parameter of SAR445514: AUClast

    Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to time of the last concentration observed above the lower limit of quantification (ie, Clast)

    Time frame: From cycle 1 to end of treatment (approx. 1 year with cycle of 28 days)

  24. Assessment of pharmacokinetics (PK) parameter of SAR445514: Cmax

    Maximum observed concentration

    Time frame: From cycle 1 to end of treatment (approx. 1 year with cycle of 28 days)

  25. Assessment of pharmacokinetics (PK) parameter of SAR445514: Tmax

    First time to reach Cmax

    Time frame: From cycle 1 to end of treatment (approx. 1 year with cycle of 28 days)

  26. Incidence of anti-drug antibody (ADA) against SAR445514

    Time frame: From cycle 1 to end of treatment (approx. 1 year with cycle of 28 days)

  27. Dose extension (Part 3 - RRMM & RRLCA) Minimum Residual Disease (MRD) negativity rate

    MRD status in participants with response of VGPR or better

    Time frame: Cycle 1 to first progressive disease or end of follow-up whichever comes first (approx. 15 months with cycle of 28 days)

07

Study locations

16 sites
  • Investigational Site Number : 0360001
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number : 0360002
    Richmond, Victoria 3121, Australia
  • Institut Jules Bordet_Site Number : 0560002
    Anderlecht, 1070, Belgium
  • Het Ziekenhuisnetwerk Antwerpen vzw - ZNA Middelheim_Site Number : 0560001-2
    Antwerp, 2020, Belgium
  • Het Ziekenhuisnetwerk Antwerpen vzw - ZNA Cadix_Site Number : 0560001-1
    Antwerp, 2030, Belgium
  • Investigational Site Number : 0560001
    Antwerp, 2060, Belgium
  • Investigational Site Number : 2030002
    Brno, 625 00, Czechia
  • Investigational Site Number : 2030001
    Ostrava, 708 52, Czechia
  • Investigational Site Number : 3480001
    Budapest, 1085, Hungary
  • Investigational Site Number : 3800001
    Rozzano, Lombardy 20089, Italy
  • Hospital Universitario Marqués de Valdecilla_Site Number : 7240001
    Santander, Cantabria 39008, Spain
  • Institut Catala d´oncologia - Badalona_Site Number : 7240002
    Badalona, Catalonia 08916, Spain
  • HOSPITAL CLINIC i PROVINCIAL BARCELONA_Site Number : 7240003
    Barcelona, 08036, Spain
  • Investigational Site Number : 8260003
    Birmingham, B15 2TH, United Kingdom
  • Investigational Site Number : 8260002
    London, NW1 2BU, United Kingdom
  • Investigational Site Number : 8260001
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05839626
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 3, 2023
Start date
May 15, 2023
Primary completion
May 26, 2025
Completion
May 26, 2025
Last update
May 27, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Myeloma→

Other studies from this sponsor

Sanofi

Start the discussion